[18F]APN-1607 PET Imaging for Alzheimer's Disease
Recruiting at 3 trial locations
TC
PC
BN
Overseen ByBrad Navia
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: APRINOIA Therapeutics, LLC
Must be taking: AD symptomatic treatment
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a special imaging agent to study brain patterns in people with mild dementia, Alzheimer's disease, and healthy individuals. The agent helps highlight abnormal brain proteins. A similar imaging agent was recently approved for visualizing amyloid.
Who Is on the Research Team?
David Russell, M.D., Ph.D
Principal Investigator
Invicro
Are You a Good Fit for This Trial?
This trial is for men and women aged 50-85, who are either not able to have children or agree to use contraception. It's for those with mild to moderate Alzheimer's Disease (MDAD), AD dementia, or healthy without cognitive impairment. Participants must be in good physical health with no relevant medical issues.Inclusion Criteria
Written informed consent must be obtained before any assessment is performed.
Has a clinical dementia rating (CDR) score of 0.
I am a woman who cannot become pregnant or will not be pregnant during the study.
See 7 more
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
PET Imaging
Participants undergo PET imaging using [18F]APN-1607 to assess uptake patterns
1 week
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after imaging
1 week
1 visit (in-person)
What Are the Treatments Tested in This Trial?
Interventions
- [18F]APN-1607
Trial Overview [18F]APN-1607 uptake patterns are being compared across individuals with MDAD, AD dementia, and healthy subjects. The goal is to see how this imaging agent behaves differently among these groups which could help in understanding and diagnosing Alzheimer's Disease.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: [18F]APN-1607Experimental Treatment1 Intervention
Subjects will undergo PET imaging using \[18F\]APN-1607.
Find a Clinic Near You
Who Is Running the Clinical Trial?
APRINOIA Therapeutics, LLC
Lead Sponsor
Trials
2
Recruited
170+
Aprinoia Therapeutics Inc.
Lead Sponsor
Trials
1
Recruited
130+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.